This paper is only available as a PDF. To read, Please Download here.
Abstract
The Ann Arbor Conference on the staging of Hodgkin's disease suggested that the prognosis
in patients with “E” stage Hodgkin's disease is similar to that in comparable patients
with only nodal disease. A comparative analysis was undertaken of 84 patients with
pathologically staged IIA to IIIA disease and 18 patients with stage IIEA to IIIEA disease. The lung was the principal site of extranodal extension (15 patients).
Both groups were treated concurrently with either extended field irradiation alone
or limited field irradiation followed by MOPP chemotherapy (nitrogen mustard, vincristine,
procarbazine and prednisone). Relapse rates after irradiation alone were 29 per cent
for the patients with stage HA to IIIA disease and 82 per cent for the patients with
“E” stage disease. Patients who received adjuvant chemotherapy had relapse rates of
6 per cent and 14 per cent, respectively. Most “E” stage relapses were regional recurrences
within the lung parenchyma. Wilcoxon analysis revealed a significantly shorter remission
duration and survival for the patients with “E” stage disease after irradiation alone,
but there were no differences between the two patient populations treated with irradiation
followed by chemotherapy. These data indicate that the prognosis in patients with
“E” stage Hodgkin's disease of the lung is poor when they are treated with irradiation
alone, and that adjuvant chemotherapy should be considered for such patients.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The American Journal of MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Report of the committee on Hodgkin's disease staging classification.Cancer Res. 1971; 31: 1860
- Prognostic and therapeutic implications of staging in extranodal Hodgkin,s disease.Cancer Res. 1971; 31: 1814
- The natural history of the lymphomas related to the clinical classification.in: Zarafonetis CJD Proceedings of the International Conference on Leukemia-Lymphoma. Lea & Febiger, Philadelphia1968: 357
- Staging laparotomy in Hodgkin's disease.Am J Med. 1974; 57: 86
- Report of the nomenclature committee.Cancer Res. 1966; 26: 1311
- Combination radiotherapy and chemotherapy in the treatment of early Hodgkin's disease.Oncology. 1973; 27: 484
- Hodgkin's Disease.Harvard University Press, Cambridge, Mass1972
- A combined modality approach to the treatment of Hodgkin's disease.Cancer. 1975; 35: 1055
- Cyclophosphamide, vinblastine, procarbazine and prednisone with CCNU and vinblastine maintenance for advanced Hodgkin,s disease.Cancer. 1977; 39: 1949
- Non-parametric estimations from incomplete observation.Am Stat Assoc J. 1958; 53: 457
- A generalized Wilcoxon test for comparing arbitrarily singly-censored samples.Biometrika. 1965; 52: 203
- Current status of clinical trials: Stanford experience, 1962–1972.Natl Cancer Inst Monogr. 1973; 36: 363
- Results of radiation therapy and implications for the clinical staging of Hodgkin:s disease.Cancer Res. 1971; 31: 1834
- Progress Report: Hodgkin's Clinical Trial, 1972.Natl Cancer Inst Monogr. 1973; 36: 387
- The place of radiotherapy in the treatment of malignant lymphoma.Clin Haematol. 1974; 3: 161
- The management of stages I, II, and III Hodgkin's disease with combined radiotherapy and chemotherapy.Cancer. 1975; 35: 55
- The management of Hodgkins disease.Cancer. 1975; 36: 796
- Evidence for a tumoricidal dose level in the radiotherapy of Hodgkin's disease.Cancer Res. 1966; 26: 1221
- The use of thin lung shields to deliver limited whole-lung irradiation during mantle-field treatment of Hodgkin:s disease.Radiology. 1971; 101: 441
Article info
Publication history
Accepted:
December 30,
1976
Footnotes
☆This study was presented in part at the XVIIIth Annual Meeting of the American Society of Hematology, Dallas, Texas, December 6–9, 1975.
Identification
Copyright
© 1977 Published by Elsevier Inc.
